Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231
Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231
复制标题
DOI：
10.1176/appi.ajp.160.2.376
复制
发表时间：
2003-02-01
影响因子：
17.7
通讯作者：
Hampel, H
中科院分区：
文献类型：
--
作者：
Buerger, K;Zinkowski, R;Hampel, H
目的：老年重度抑郁症与阿尔茨海默病的区分因症状重叠而受到阻碍。脑脊液中 231 位苏氨酸磷酸化的 tau 蛋白 (p-tau(231)) 浓度升高被认为是阿尔茨海默病的生物标志物。作者询问 p-tau231 水平是否可以改善老年重度抑郁症和阿尔茨海默病之间的鉴别诊断。方法：包括 34 名抑郁症受试者、64 名可能患有阿尔茨海默病、17 名可能患有阿尔茨海默病和 21 名健康对照受试者。采用酶联免疫吸附测定法测量 P-tau (231) 浓度。结果：阿尔茨海默病患者的 P-tau (231) 水平显着高于老年重度抑郁症患者和健康对照受试者。为了区分可能的阿尔茨海默病和重度抑郁症，p-tau(231) 正确分配了 87% 的受试者。当将可能的轻度阿尔茨海默病与重度抑郁症进行比较时，p-tau(231)正确分配了78%的受试者。结论：脑脊液p-tau(231)应作为区分老年抑郁症和阿尔茨海默病的潜在生物标志物进行评估。
Objective: Differentiation of geriatric major depression from Alzheimer's disease is hampered by overlapping symptoms. Increased CSF concentrations of tau protein phosphorylated at threonine 231 (p-tau(231)) have been suggested as a biomarker for Alzheimer's disease. The authors asked whether p-tau231 levels improve the differential diagnosis between geriatric major depression and Alzheimer's disease.Method: Included were 34 depression subjects, 64 with probable Alzheimer's disease, 17 with possible Alzheimer's disease, and 21 healthy comparison subjects. P-tau(231) concentrations were measured with an enzyme-linked immunosorbent assay.Results: P-tau(231) levels were significantly higher in Alzheimer's disease than in geriatric major depression patients and healthy comparison subjects. For differentiation of probable Alzheimer's disease from major depression, p-tau(231) correctly allocated 87% of subjects. When possible mild Alzheimer's disease was compared to major depression, p-tau(231) correctly allocated 78% of subjects.Conclusions: CSF p-tau(231) should be evaluated as a potential biological marker for differentiation of geriatric depression from Alzheimer's disease.